The HealthCare segment of
) has several drugs in its portfolio. Xarelto is one of the key
revenue drivers at the segment. Xarelto is approved for several
indications in the U.S. including stroke prevention in
non-valvular atrial fibrillation, deep vein thrombosis (DVT),
pulmonary embolism (PE) and reducing the risk of recurrent DVT
and PE. Xarelto is marketed by
Johnson & Johnson
) in the U.S. and by Bayer outside the U.S.
BAYER A G -ADR (BAYRY): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
Last week Bayer announced the publication of positive data from
the phase III EINSTEIN study on Xarelto in the
Journal. The EINSTEIN program is evaluating Xarelto in comparison
to a dual-drug regimen of low molecular weight heparin (LMWH) and
vitamin K antagonist (VKA) as a treatment of DVT and PE and the
prevention of recurrent DVT and PE.
Results from the study revealed that Xarelto had a lower rate and
severity of major bleeding in comparison to the dual-drug therapy
of LMWH and VKA. Xarelto also improved treatment satisfaction in
comparison to the dual-drug therapy.
Bayer and Johnson & Johnson are looking to expand Xarelto's
indication further. Successful label expansion will boost the
sales potential of the drug. In May this year, Xarelto was
approved in the EU for the prevention of atherothrombotic events
(cardiovascular death, myocardial infarction or stroke) after an
ACS in adults suffering from elevated cardiac biomarkers at a
dose of 2.5 mg twice-daily (BID) in combination with antiplatelet
In the second quarter of 2013, Xarelto sales increased 237.4%
year over year to €219 million.
Bayer, a large-cap pharma company, presently carries a Zacks Rank
#2 (Buy) and so does another large-cap peer
Eli Lilly and Company
). Meanwhile, large-cap stocks such as
) look more attractive with a Zacks Rank #1 (Strong Buy).